4957 |
Residual Ischemic Risk and Benefit of Prolonged DAPT; Update Latest Clinical Trials |
Jin Joo Park |
Apr. 27. 19 |
4956 |
Renal Denervation Works: Why Can\'t We Prove It? |
James R. Margolis |
Apr. 27. 19 |
4955 |
Durability of Balloon-Expandable Transcatheter Heart Valve |
Alain G. Cribier |
Apr. 27. 19 |
4954 |
Sapien 3 THV with Future Coronary Access |
Alan C. Yeung |
Apr. 27. 19 |
4953 |
Current Status of Balloon-Expandable TAVR in Korea |
Jung-Min Ahn |
Apr. 27. 19 |
4952 |
Results and Update from the Vessix RE-INFORCE Program |
Martin Bert Leon |
Apr. 27. 19 |
4951 |
Global Update : Low-Risk TAVR |
Vinayak Bapat |
Apr. 27. 19 |
4950 |
Results and Update from the SPYRAL Hypertension Program(OFF-MED and ON-MED Trials) |
David E. Kandzari |
Apr. 27. 19 |
4949 |
RADIANCE HTN SOLO Off Trial: ReCor Medical Paradise Technology and Results |
Byeong-Keuk Kim |
Apr. 27. 19 |
4948 |
Invited Case Presentation & Focus Review: A LAD CTO of Retrograde Approach Via Septal Channel; Channel Selection and Negotiation |
Satoru Otsuji |
Apr. 27. 19 |